This week: how quickly weight returns after stopping semaglutide or tirzepatide, why a borderline normal haemoglobin may deserve a closer look, twelve month results for automated insulin delivery in type 1 diabetes, why the testosterone dose matters for heart rhythm, and what two million people can and cannot tell us about drinks and mood.

In this episode.

Weight regain after stopping a GLP-1, from a pooled analysis of six randomised trials in Endocrinology, Diabetes and Metabolism.

Borderline low haemoglobin and mortality, from half a million adults in the UK Biobank, published in Annals of Internal Medicine.

Automated insulin delivery at twelve months in adults with type 1 diabetes.

Testosterone and atrial fibrillation, and why the target level matters, from the Journal of the Endocrine Society.

Drinks, depression and anxiety, from fifty-nine studies covering more than two million people.

Every story carries its caveat in the episode. Correlation is not causation, and preliminary findings are flagged as preliminary.

This is general education, not personal medical advice. Please talk to your own clinician about your care.

This week: a large trial finds statins cut heart attacks and strokes in healthy over seventies but do not prevent dementia or disability, a Scandinavian study of more than 280,000 people pins down who is most at risk of ketoacidosis on flozin medicines, semaglutide and tirzepatide enter the European heart failure guidelines, immune cells appear to remember obesity for years, and four medical bodies issue joint autumn vaccine advice.

statins, atorvastatin, STAREE trial, primary prevention, healthy ageing, SGLT2 inhibitors, flozins, diabetic ketoacidosis, sick day rules, type 2 diabetes, heart failure, ESC guidelines, semaglutide, tirzepatide, GLP-1, obesity, weight loss, immune system, flu vaccine, COVID vaccine, RSV